Supplying our medicines

during the Brexit transition

Lilly’s top priority is to ensure patients in the UK and in the EU can continue to access the medicines they rely on.

This has required us to plan for a worst-case “hard Brexit” and we have undertaken comprehensive analysis of the risks this could pose across our business and, critically, to our ability to supply medicines in the UK.  Lilly has worked with Government, the NHS and the broader health system through this process, providing expertise and data to support national contingency planning and cooperating with the Department of Health and Social Care’s stockpiling strategy, first for the March deadline, and again for 31 October.

We recognise that patients, pharmacists, and doctors, are particularly concerned about the supply of medicines in a “no-deal” Brexit scenario.  Lilly’s own Brexit investment has been significant. In most cases our planning, including our own medicines stockpiling, exceeds government guidance. Right now, we are maintaining 16 weeks’ supply of medicines in the UK, which includes all of our insulins in different doses. We are continually monitoring our stock levels and have delivery trucks bringing medicines into the UK at least 6 times a week and are ready to increase our supplies as needed.

While Lilly has done everything in its power to prepare for Brexit, circumstances outside of our responsibility could still disrupt medicines supply. This includes delays at ports of entry, freight capacity on sea and air routes, volatility in demand for medicines due to stockpiling outside of our supply chain, and unpredictable fluctuations in parallel import and export.    

Patients should not be disadvantaged by the UK leaving the EU and our focus will remain firmly on ensuring we can supply Lilly medicines to the patients that need them.

In the event that a pharmacist is having difficulty accessing Lilly medicines, they should contact Lilly in the usual way.